BREAKING NEWS Car of missing North Iowa man contained human remains Full Story

FDA re-examines safety of controversial new drug

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concern...

Posted: Apr 25, 2018 6:38 PM
Updated: Apr 25, 2018 6:38 PM

The Food and Drug Administration says it is re-examining the safety of a medication that was approved despite concerns that not enough was known about the drug's risks.

In response to questioning at a budget hearing last week, FDA Commissioner Scott Gottlieb told members of Congress that he would "take another look" at Nuplazid, which is the only drug approved to treat hallucinations and delusions associated with Parkinson's disease psychosis. The medication has been cited as a so-called "suspect" medication in hundreds of deaths voluntarily reported by caregivers, doctors and other medical professionals since it hit the market, as highlighted in a recent CNN report.

The FDA told CNN this week that the agency had already begun conducting a new evaluation of the medication when Gottlieb was questioned about it at the hearing. The agency said the review had started several weeks ago.

"What does it take for a drug like this to be taken off the market?" asked US Rep. Rosa DeLauro, a member and former chair of the congressional subcommittee responsible for funding and overseeing the FDA.

Read CNN's investigation: FDA worried drug was risky; now reports of deaths spark concern

DeLauro pressed Gottlieb for answers on his agency's response to the safety concerns surrounding Nuplazid.

"How many more adverse events do we have to have reported? How many people, quite frankly, have to die? Why does the industry always take precedence over public health and safety?"

Tracked by the FDA, the adverse event reports cited by DeLauro do not mean that a suspected medication has been ruled the cause of harm and are typically not the result of official investigations. But the FDA uses the information to monitor potential issues with a drug and can take action as needed: updating a medication's label, for instance, or restricting its use. In rare cases, the agency can even pull a drug off the market.

When asked by CNN about what prompted the FDA's new evaluation of Nuplazid, the agency said the decision was based on a number of factors but wouldn't say what those factors were. Instead, it would only comment generally, saying that it identifies "potential signals of serious risk/new safety information" in part by using adverse event data and that the agency is not suggesting physicians stop prescribing the drug or take patients off of it while a safety evaluation is taking place.

The FDA has noted that the death reports citing Nuplazid have typically involved elderly patients with advanced-stage Parkinson's disease who suffered from numerous medical conditions and often take other medications that can increase the risk of death.

But physicians, researchers and other medical experts told CNN that the high number of reports deserved a closer look to determine whether they were related to the drug. They also recommended further testing of Nuplazid, worrying that the drug had been approved too quickly, based on too little evidence that it was safe or effective.

Nuplazid's review was expedited by the FDA because it had been designated a "breakthrough therapy," meaning it demonstrated "substantial improvement" in patients with serious or life-threatening diseases compared to treatments already on the market.

Dr. Paul Andreason, the physician who led the FDA's medical review of Nuplazid, warned that patients taking the drug during the company's clinical trials experienced serious outcomes, including death, at more than double the rate of those taking the placebo. But the FDA ruled that the potential benefits outweighed the risks, agreeing with an advisory committee that cited a lack of safe alternatives and the pleas from family members who claimed the drug was already helping or could help their loved ones.

At that advisory committee meeting two years ago, one woman said that her grandmother had been part of the clinical trials for the drug and that Nuplazid had been life-changing.

"We didn't know what to expect or even if she was on the drug" or a placebo, said Zoey Wade. "We soon realized that she must be taking the drug, because she really returned to herself. Her hallucinations reduced, and she better understood what was real and what was imaginary."

Shortly after Nuplazid's release, however, patients' family members, doctors and other health care professionals started reporting "adverse events" possibly linked to the medication -- including deaths, life-threatening incidents, falls, insomnia, nausea and fatigue.

During the first 10 months Nuplazid was on the market, 244 deaths were reported to the FDA in which Nuplazid was a "suspect" medication, according to an analysis conducted by the Institute for Safe Medication Practices. FDA data now show that the number of reported deaths has risen to more than 700. In more than 1,000 reports, patients continued to experience hallucinations while on Nuplazid.

After CNN published its investigation on Nuplazid, reporters were contacted by family members who said the drug helped tame hallucinations with few apparent side effects and others who said they believe Nuplazid contributed to their family member's decline or death. Some said they had not yet reported these experiences to the drugmaker or the FDA.

While the FDA has long been criticized for being too slow to approve drugs, DeLauro seized on its push to streamline the process, lambasting the agency for putting industry interests and efficiency above public health and safety.

DeLauro described the number of adverse events and deaths as "staggering" and "unprecedented." She also expressed concern that the drugmaker, Acadia Pharmaceuticals, is attempting to get the drug approved for a larger population: patients who suffer from dementia-related psychosis.

"I don't know why it should stay on the market, especially when the FDA has not determined it to be safe and while the number of adverse events continues to soar," she told Gottlieb.

In response to the congresswoman's remarks, Acadia told CNN that adverse event data alone are "not a comprehensive and accurate indicator of the safety profile of any drug." In response to CNN's earlier report on the drug, Acadia said there are a number of reasons for the higher volume of death reports, including the fact that the company distributes Nuplazid through a network of specialty pharmacies that puts the company in more frequent contact with both patients and caregivers -- meaning Acadia is more likely to receive reports of death, which it is required to pass along to the FDA.

Commissioner Gottlieb told the committee that the FDA is careful about the decisions it makes and that there may be a higher tolerance for risk in situations where there is an unmet medical need, "so long as the patient is properly informed of what those risks are." This echoed what he told CNN's Dr. Sanjay Gupta in an interview earlier this month.

The FDA previously told CNN that it was aware of Nuplazid's "complex safety profile" at the time of approval and required the drugmaker to place warnings on its labeling. The agency also said that, though it was continuing to monitor available information about Nuplazid, it had "not identified a specific safety issue" not already reflected on the medication's label.

DeLauro's office told CNN that it plans to follow up with the FDA about its inquiry into Nuplazid.

Do you have information to share about Nuplazid or other drugs targeting the elderly? Email us: watchdog@cnn.com.

Minnesota Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 135372

Reported Deaths: 2406
CountyConfirmedDeaths
Hennepin34290991
Ramsey14168361
Dakota9897138
Anoka8872150
Washington598672
Stearns588344
Scott342934
Olmsted327730
St. Louis302669
Wright254115
Clay232843
Nobles227616
Blue Earth20457
Carver18207
Sherburne171122
Kandiyohi17055
Rice164810
Mower152917
Winona126019
Chisago10402
Crow Wing103522
Lyon9766
Benton9509
Waseca9299
Beltrami9017
Otter Tail8737
Todd8266
Steele7613
Morrison7429
Nicollet73917
Itasca73617
Douglas7083
Freeborn6844
Polk6734
Le Sueur6315
Martin61317
McLeod6024
Goodhue59711
Watonwan5794
Becker5754
Isanti5615
Pine5490
Carlton4441
Chippewa4443
Mille Lacs41315
Hubbard3962
Dodge3940
Wabasha3840
Cass3775
Pipestone35117
Rock3404
Meeker3313
Brown3243
Unassigned29253
Yellow Medicine2856
Murray2833
Cottonwood2820
Redwood28111
Roseau2650
Fillmore2640
Renville25611
Sibley2543
Wadena2393
Faribault2350
Jackson2151
Kanabec21510
Swift2071
Houston2061
Pennington1951
Lincoln1840
Stevens1841
Aitkin1792
Koochiching1704
Pope1610
Big Stone1410
Lac qui Parle1403
Wilkin1374
Marshall1261
Lake1230
Norman1170
Mahnomen1162
Clearwater1140
Grant994
Red Lake782
Traverse570
Lake of the Woods441
Kittson420
Cook170

Iowa Coronavirus Cases

Data is updated nightly.

Confirmed Cases: 116514

Reported Deaths: 1643
CountyConfirmedDeaths
Polk19024288
Woodbury724797
Johnson586230
Black Hawk562698
Linn5591132
Dubuque521157
Scott456639
Story401018
Dallas346344
Pottawattamie324744
Sioux244716
Buena Vista226112
Marshall202036
Webster184415
Plymouth166728
Wapello153062
Clinton149226
Muscatine147758
Des Moines139610
Cerro Gordo137726
Crawford136114
Warren12617
Carroll115612
Jasper111234
Henry10675
Marion101810
Lee95610
Tama94837
Delaware78013
Dickinson7417
Wright7271
Boone7239
Mahaska69724
Bremer6779
Washington66211
Harrison65815
Jackson6333
Benton5902
Lyon5537
Clay5354
Louisa52315
Winnebago49719
Hardin4777
Winneshiek4779
Hamilton4754
Cedar4746
Kossuth4690
Poweshiek45911
Buchanan4544
Jones4474
Floyd43711
Emmet43019
Clayton4233
Iowa4109
Page4060
Mills4053
Cherokee4032
Sac3994
Guthrie39515
Cass3903
Butler3832
Fayette3814
Franklin38118
Shelby3732
Allamakee3719
Madison3623
Chickasaw3611
Clarke3523
Humboldt3253
Hancock3204
Palo Alto3142
Grundy3115
Calhoun3094
Osceola2851
Mitchell2811
Howard2709
Monroe25911
Monona2451
Taylor2432
Jefferson2391
Union2314
Appanoose2273
Pocahontas2262
Fremont2061
Lucas2056
Ida1932
Greene1870
Van Buren1802
Davis1784
Montgomery1787
Adair1701
Keokuk1611
Decatur1500
Audubon1481
Worth1450
Wayne1213
Ringgold882
Adams810
Unassigned110
Rochester
Clear
29° wxIcon
Hi: 31° Lo: 25°
Feels Like: 15°
Mason City
Clear
31° wxIcon
Hi: 34° Lo: 24°
Feels Like: 19°
Albert Lea
Clear
30° wxIcon
Hi: 31° Lo: 25°
Feels Like: 20°
Austin
Clear
30° wxIcon
Hi: 32° Lo: 25°
Feels Like: 21°
Charles City
Clear
28° wxIcon
Hi: 36° Lo: 24°
Feels Like: 20°
Tracking plenty of sunshine through the week!
KIMT Radar
KIMT Eye in the sky

Community Events